Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GLB002
MIFTS: 74

Glioblastoma

Categories: Rare diseases, Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Glioblastoma

About this section

MalaCards integrated aliases for Glioblastoma:

Name: Glioblastoma 49 55 28 51 69
Glioblastoma Multiforme 49 55 69
Gbm 55

Characteristics:

Orphanet epidemiological data:

55
glioblastoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Europe),1-9/100000 (United States); Age of onset: All ages; Age of death: adult;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 55  
Rare neurological diseases


External Ids:

Orphanet 55 ORPHA360
MESH via Orphanet 42 D005909
UMLS via Orphanet 70 C0017636 C1621958
ICD10 via Orphanet 33 C71.9
UMLS 69 C1621958
Sources

Summaries for Glioblastoma

About this section
NIH Rare Diseases : 49 Glioblastoma is a malignant (cancerous) brain tumor that develops from a specific type of brain cell called an astrocyte. These cells help support and nourish neurons (nerve cells of the brain) and form scar tissue that helps repair brain damage in response to injury. Glioblastomas are often very aggressive and grow into surrounding brain tissue. Signs and symptoms, such as headache, nausea, vomiting and/or drowsiness, may develop when the tumor begins to put excess pressure on the brain. Affected people may also experience other features depending on the size and location of the tumor. In most cases, the exact underlying cause is unknown; however, they can rarely occur in people with certain genetic syndromes such as neurofibromatosis type 1, Turcot syndrome and Li Fraumeni syndrome. There is currently no cure for glioblastoma. Treatment is palliative and may include surgery, radiation therapy and/or chemotherapy. Last updated: 1/19/2015

MalaCards based summary : Glioblastoma, also known as glioblastoma multiforme, is related to giant cell glioblastoma and glioma susceptibility 1, and has symptoms including abnormal cell morphology, visual loss and abnormality of the corpus callosum. An important gene associated with Glioblastoma is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Dacarbazine and Temozolomide have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and endothelial, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Glioblastoma

About this section

Diseases related to Glioblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 367)
# Related Disease Score Top Affiliating Genes
1 giant cell glioblastoma 34.3 BRAF EGFR FGFR1 IDH1 MGMT PTEN
2 glioma susceptibility 1 34.3 ERBB2 IDH1 TP53
3 gliosarcoma 33.7 CDK4 EGFR FGFR1 IDH1 MGMT PTEN
4 glioblastoma multiforme 33.3 AKT3 BRAF CDK2 CDK4 DMBT1 EGFR
5 gliomatosis cerebri 33.2 EGFR IDH1 PTEN TP53
6 astrocytoma 31.5 CDK4 DMBT1 EGFR FGFR1 IDH1 MGMT
7 oligodendroglioma 31.2 EGFR IDH1 MGMT PDGFRA PTEN TP53
8 glioma 31.2 AKT3 CDK4 DMBT1 EGFR ERBB2 IDH1
9 medulloblastoma 31.1 DMBT1 ERBB2 MGMT PDGFRA TP53
10 pleomorphic xanthoastrocytoma 31.0 BRAF IDH1 MGMT TP53
11 brain cancer 30.8 DMBT1 EGFR IDH1 MGMT PTEN TP53
12 anaplastic oligodendroglioma 30.8 EGFR IDH1 MGMT
13 malignant glioma 30.8 CDK4 DMBT1 EGFR MGMT PDGFRA PTEN
14 small cell carcinoma 30.6 EGFR PDGFRA PTEN TP53
15 li-fraumeni syndrome 30.6 EGFR IDH1 PTEN TP53
16 pilocytic astrocytoma 30.6 BRAF CDK4 FGFR1 HRAS IDH1 MGMT
17 mixed glioma 30.4 IDH1 PDGFRA TP53
18 spinal cord astrocytoma 30.4 IDH1 MGMT TP53
19 soft tissue sarcoma 30.4 EGFR TP53 VEGFA
20 melanoma 30.4 AKT3 BRAF CDK4 HRAS PDGFRA PTEN
21 ring chromosome 7 30.3 CDK4 TP53
22 adenocarcinoma 30.2 BRAF EGFR ERBB2 HRAS TP53 VEGFA
23 leiomyosarcoma 30.2 CDK4 PDGFRA TP53
24 grade iii astrocytoma 30.1 CDK4 DMBT1 EGFR MGMT PDGFRA PTEN
25 intrahepatic cholangiocarcinoma 30.1 EGFR IDH1 TP53
26 hepatocellular carcinoma 30.0 CDK2 CDK4 EGFR HRAS MTOR PTEN
27 bladder cancer 29.9 CDK4 EGFR ERBB2 HRAS TP53 VEGFA
28 prostate cancer 29.9 AKT3 CDK2 CDK4 EGFR ERBB2 FGFR1
29 ovarian cancer 29.9 AKT3 BRAF CDK4 EGFR ERBB2 PTEN
30 pancreatic cancer 29.8 CDK4 EGFR ERBB2 HRAS MTOR TP53
31 breast cancer 29.5 CDK2 CDK4 EGFR ERBB2 FGFR1 HRAS
32 colorectal cancer 29.3 BRAF CDK2 CDK4 EGFR ERBB2 HRAS
33 lung cancer 29.3 BRAF CDK2 CDK4 DMBT1 EGFR ERBB2
34 brain glioblastoma multiforme 12.1
35 glioblastoma proneural subtype 12.1
36 glioblastoma classical subtype 12.1
37 glioblastoma mesenchymal subtype 12.1
38 glioblastoma neural subtype 12.1
39 goodpasture syndrome 12.0
40 adult spinal cord glioblastoma multiforme 12.0
41 glioma susceptibility 3 11.5
42 mismatch repair cancer syndrome 11.2
43 glioma susceptibility 2 10.8
44 glioma susceptibility 9 10.8
45 breast intraductal proliferative lesion 10.8 EGFR ERBB2
46 microglandular adenosis 10.8 EGFR ERBB2 TP53
47 fibrillary astrocytoma 10.8 IDH1 MGMT TP53
48 luminal breast carcinoma 10.8 EGFR ERBB2 MTOR
49 periosteal osteogenic sarcoma 10.8 CDK4 IDH1 TP53
50 hidradenocarcinoma 10.8 EGFR ERBB2 TP53

Graphical network of the top 20 diseases related to Glioblastoma:



Diseases related to Glioblastoma
Sources

Symptoms & Phenotypes for Glioblastoma

About this section

Human phenotypes related to Glioblastoma:

55 31 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormal cell morphology 55 31 hallmark (90%) Very frequent (99-80%) HP:0025461
2 visual loss 55 31 frequent (33%) Frequent (79-30%) HP:0000572
3 abnormality of the corpus callosum 55 31 frequent (33%) Frequent (79-30%) HP:0001273
4 muscle weakness 55 31 frequent (33%) Frequent (79-30%) HP:0001324
5 mood changes 55 31 frequent (33%) Frequent (79-30%) HP:0001575
6 cerebral edema 55 31 frequent (33%) Frequent (79-30%) HP:0002181
7 headache 55 31 frequent (33%) Frequent (79-30%) HP:0002315
8 language impairment 55 31 frequent (33%) Frequent (79-30%) HP:0002463
9 paralysis 55 31 frequent (33%) Frequent (79-30%) HP:0003470
10 fatigue 55 31 frequent (33%) Frequent (79-30%) HP:0012378
11 seizures 55 31 occasional (7.5%) Occasional (29-5%) HP:0001250
12 memory impairment 55 31 occasional (7.5%) Occasional (29-5%) HP:0002354
13 glioblastoma 55 Obligate (100%)
14 abnormality of the cerebral white matter 55 Frequent (79-30%)
15 abnormality of nervous system physiology 55 Frequent (79-30%)
16 glioblastoma multiforme 31 obligate (100%) HP:0012174

UMLS symptoms related to Glioblastoma:


seizures, headache

GenomeRNAi Phenotypes related to Glioblastoma according to GeneCards Suite gene sharing:

25 (show all 29)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.16 BRAF EGFR MTOR HRAS
2 Decreased viability GR00107-A-1 11.16 PRKCA
3 Decreased viability GR00173-A 11.16 PDGFRA
4 Decreased viability GR00221-A-1 11.16 EGFR MTOR PDGFRA PRKCA AKT3 PRKCB
5 Decreased viability GR00221-A-2 11.16 PRKCA AKT3 HRAS PRKCB FGFR1 CDK2
6 Decreased viability GR00221-A-3 11.16 ERBB2 PDGFRA AKT3 HRAS CDK2
7 Decreased viability GR00221-A-4 11.16 BRAF EGFR ERBB2 MTOR PDGFRA PRKCA
8 Decreased viability GR00301-A 11.16 AKT3 BRAF CDK2
9 Decreased viability GR00342-S-1 11.16 MTOR PRKCA
10 Decreased viability GR00342-S-2 11.16 MTOR PRKCA
11 Decreased viability GR00342-S-3 11.16 PRKCA
12 Decreased viability GR00381-A-1 11.16 BRAF
13 Decreased substrate adherent cell growth GR00193-A-1 10.63 CDK2 PRKCB
14 Decreased substrate adherent cell growth GR00193-A-2 10.63 AKT3 CDK2 CDK4 EGFR MTOR PRKCB
15 Decreased substrate adherent cell growth GR00193-A-3 10.63 AKT3 CDK2 CDK4 BRAF
16 Decreased substrate adherent cell growth GR00193-A-4 10.63 CDK2 CDK4 BRAF FGFR1
17 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 10.22 EGFR ERBB2 HRAS MTOR PRKCA PRKCB
18 Decreased cell migration GR00055-A-1 10.18 AKT3 BRAF CDK4 EGFR HRAS MTOR
19 Decreased viability with paclitaxel GR00179-A-1 10.06 MTOR EGFR ERBB2
20 Decreased viability with paclitaxel GR00179-A-2 10.06 MTOR
21 Decreased viability with paclitaxel GR00179-A-3 10.06 EGFR MTOR
22 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.91 BRAF FGFR1 MTOR PRKCA PRKCB PRKCH
23 Decreased cell proliferation GR00353-A 9.81 AKT3 CDK2 ERBB2 MTOR
24 Increased cell death HMECs cells GR00103-A-0 9.8 PTEN TP53 CDK2 EGFR FGFR1 PRKCA
25 Decreased Hepatitis C Virus pseudoparticles (HCVpp GR00234-A-1 9.76 BRAF CDK2 CDK4 EGFR
26 Increased cell migration GR00055-A-3 9.7 BRAF EGFR HRAS MTOR PRKCA PRKCB
27 Decreased cella89culturea89derived Hepatitis C virus (HCVcc GR00234-A-2 9.67 EGFR BRAF CDK4
28 Increased cell viability after pRB stimulation GR00230-A-1 9.43 AKT3 CDK2 CDK4 EGFR ERBB2 PRKCA
29 Increased colony dispersion (increased number of colonies and decreased number of cells per colony) GR00212-A 8.92 MTOR PDGFRA PRKCA FGFR1

MGI Mouse Phenotypes related to Glioblastoma:

43 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.54 PTEN TP53 VEGFA AKT3 BRAF CDK2
2 cardiovascular system MP:0005385 10.49 AKT3 BRAF CDK2 CDK4 EGFR ERBB2
3 cellular MP:0005384 10.46 EGFR ERBB2 FGFR1 MTOR PDGFRA PRKCA
4 endocrine/exocrine gland MP:0005379 10.46 AKT3 BRAF CDK2 CDK4 EGFR ERBB2
5 growth/size/body region MP:0005378 10.45 FGFR1 HRAS IDH1 MTOR PDGFRA PRKCH
6 mortality/aging MP:0010768 10.44 AKT3 BRAF CDK2 CDK4 DMBT1 EGFR
7 immune system MP:0005387 10.42 AKT3 BRAF CDK2 CDK4 DMBT1 EGFR
8 hematopoietic system MP:0005397 10.41 AKT3 BRAF CDK2 CDK4 EGFR FGFR1
9 behavior/neurological MP:0005386 10.4 AKT3 BRAF CDK4 ERBB2 FGFR1 HRAS
10 embryo MP:0005380 10.37 BRAF CDK2 CDK4 DMBT1 EGFR ERBB2
11 integument MP:0010771 10.35 BRAF CDK2 CDK4 EGFR ERBB2 FGFR1
12 neoplasm MP:0002006 10.35 CDK2 CDK4 DMBT1 EGFR ERBB2 HRAS
13 digestive/alimentary MP:0005381 10.34 BRAF CDK4 DMBT1 EGFR ERBB2 FGFR1
14 nervous system MP:0003631 10.3 AKT3 BRAF CDK4 EGFR ERBB2 FGFR1
15 muscle MP:0005369 10.27 PDGFRA PRKCA PTEN TP53 VEGFA BRAF
16 craniofacial MP:0005382 10.21 BRAF EGFR ERBB2 FGFR1 HRAS PDGFRA
17 normal MP:0002873 10.18 AKT3 BRAF EGFR ERBB2 FGFR1 HRAS
18 limbs/digits/tail MP:0005371 10.07 EGFR ERBB2 FGFR1 PDGFRA PTEN TP53
19 renal/urinary system MP:0005367 10.06 BRAF CDK4 DMBT1 EGFR FGFR1 HRAS
20 no phenotypic analysis MP:0003012 10.03 EGFR FGFR1 HRAS MGMT MTOR PDGFRA
21 reproductive system MP:0005389 10 AKT3 BRAF CDK2 CDK4 EGFR ERBB2
22 respiratory system MP:0005388 9.9 TP53 VEGFA BRAF EGFR ERBB2 HRAS
23 pigmentation MP:0001186 9.85 BRAF CDK4 EGFR PDGFRA PTEN TP53
24 skeleton MP:0005390 9.7 PTEN TP53 VEGFA BRAF EGFR ERBB2
25 vision/eye MP:0005391 9.28 BRAF CDK2 CDK4 EGFR FGFR1 PRKCH
Sources

Drugs & Therapeutics for Glioblastoma

About this section

Drugs for Glioblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 581)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
3
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
4 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
5 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
6
Ethanol Approved Phase 2, Phase 3,Phase 1,Early Phase 1 64-17-5 702
7
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
8
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 97682-44-5, 100286-90-6 60838
9
Melphalan Approved Phase 2, Phase 3 148-82-3 460612 4053
10
Carboplatin Approved Phase 2, Phase 3, Phase 1 41575-94-4 10339178 38904 498142
11
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
12
Aminolevulinic acid Approved Phase 3,Phase 2,Phase 1 106-60-5 137
13
Hydroxychloroquine Approved Phase 2, Phase 3,Phase 1 118-42-3 3652
14
Procarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 671-16-9 4915
15
Iodine Approved, Investigational Phase 3,Phase 2,Phase 1 7553-56-2 807
16
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
17
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
18 Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
19
Sunitinib Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 341031-54-7, 557795-19-4 5329102
20
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1 13010-47-4 3950
21
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
22
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1 154-93-8 2578
23
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
24
Flucytosine Approved, Investigational Phase 2, Phase 3,Phase 1 2022-85-7 3366
25
Trioxsalen Approved Phase 3,Phase 2,Phase 1 3902-71-4 5585
26
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
27
chloroquine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 54-05-7 2719
28
Morphine Approved, Investigational Phase 3 57-27-2 5288826
29
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
30
Valproic Acid Approved, Investigational Phase 3,Phase 2,Phase 1 99-66-1 3121
31
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
32
Histamine Approved, Investigational Phase 3,Phase 2 51-45-6, 75614-87-8 774
33
Copper Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 7440-50-8 27099
34
Methylphenidate Approved, Investigational Phase 3 20748-11-2, 113-45-1 4158
35
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5282379 5538
36
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
37
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 6442177
38
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
39
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 46835353 6436030 5284616
40
nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
41
Dopamine Approved Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
42
Disulfiram Approved Phase 2, Phase 3,Phase 1,Early Phase 1 97-77-8 3117
43
Povidone-iodine Approved Phase 3 25655-41-8
44
Povidone Approved Phase 3 9003-39-8
45
Losartan Approved Phase 3 114798-26-4 3961
46
Angiotensin II Approved, Investigational Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
47
Meloxicam Approved, Vet_approved Phase 2, Phase 3 71125-38-7 54677470 5281106
48
Ephedrine Approved Phase 3 299-42-3 9294
49
Pseudoephedrine Approved Phase 3 90-82-4 7028
50
Norepinephrine Approved Phase 3 51-41-2 439260

Interventional clinical trials:

(show top 50) (show all 1297)

# Name Status NCT ID Phase Drugs
1 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4 Temozolomide
2 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
3 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Recruiting NCT02520635 Phase 4 supra-early TEMODAL® chemotherapy;standard TEMODAL® chemotherapy
4 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
5 Metronomic Temozolamide in Patients With Recurrent Glioblastoma Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
6 The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients Unknown status NCT02623231 Phase 2, Phase 3 Escitalopram;placebo
7 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
8 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
9 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
10 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Completed NCT00807027 Phase 3 Activated T lymphocyte(Immuncell-LC)
11 Nimotuzumab in Adults With Glioblastoma Multiforma Completed NCT00753246 Phase 3 nimotuzumab
12 Enzastaurin Versus Lomustine in Glioblastoma Completed NCT00295815 Phase 3 enzastaurin;lomustine
13 Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients Completed NCT01149109 Phase 3 Temozolomide and lomustine;Temozolomide
14 Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT01364064 Phase 3 TMZ
15 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status Completed NCT00689221 Phase 3 Cilengitide;Temozolomide
16 Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma Completed NCT00777153 Phase 3 Cediranib;Cediranib;Lomustine Chemotherapy;Placebo Cediranib
17 Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme Completed NCT01450449 Phase 3
18 Chloroquine for Treatment of Glioblastoma Multiforme Completed NCT00224978 Phase 3 Chloroquine
19 The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
20 Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme Completed NCT00068952 Phase 3 Edotecarin;Temozolomide;Carmustine (BCNU);Lomustine (CCNU)
21 Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3 Imatinib mesylate;Hydroxyurea
22 Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
23 Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) Completed NCT00335075 Phase 3 Temozolomide;Semustine
24 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
25 A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma Completed NCT00943826 Phase 3 Bevacizumab;Temozolomide;Placebo
26 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00482677 Phase 3 temozolomide
27 Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00006353 Phase 3 temozolomide
28 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
29 Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme Completed NCT00002545 Phase 3 carmustine
30 SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
31 Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) Completed NCT00379470 Phase 3
32 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00916409 Phase 3 Temozolomide
33 Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors Completed NCT00088400 Phase 3 TransMID
34 S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
35 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
36 Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly Completed NCT01502241 Phase 3 Temozolomide
37 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
38 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
39 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
40 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
41 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
42 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
43 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
44 Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme Recruiting NCT02685605 Phase 3 Temozolomide
45 Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma Recruiting NCT01507506 Phase 3
46 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects Recruiting NCT03393000 Phase 3 Trans Sodium Crocetinate plus SOC
47 Disulfiram in Recurrent Glioblastoma Recruiting NCT02678975 Phase 2, Phase 3 Disulfiram;Alkylating Agents
48 Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III Recruiting NCT02761070 Phase 3 Temozolomide;Bevacizumab
49 A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification Recruiting NCT02573324 Phase 3 Temozolomide;ABT-414;Placebo for ABT-414
50 Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Recruiting NCT02152982 Phase 2, Phase 3 Temozolomide;Veliparib

Search NIH Clinical Center for Glioblastoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :
Sources

Genetic Tests for Glioblastoma

About this section

Genetic tests related to Glioblastoma:

# Genetic test Affiliating Genes
1 Glioblastoma 28
Sources

Anatomical Context for Glioblastoma

About this section

MalaCards organs/tissues related to Glioblastoma:

38
Brain, T Cells, Endothelial, Bone, Testes, Spinal Cord, Prostate
Sources

Publications for Glioblastoma

About this section

Articles related to Glioblastoma:

(show top 50) (show all 4164)
# Title Authors Year
1
Sodium butyrate induces senescence and inhibits the invasiveness of glioblastoma cells. ( 29434841 )
2018
2
Serum HOTAIR and GAS5 levels as predictors of survival in patients with glioblastoma. ( 28926136 )
2018
3
Glioblastoma arising within sites of encephalomalacia from cerebrovascular insult: two cases and a review of the literature. ( 29422364 )
2018
4
Magnetic Resonance Imaging-Guided Laser Interstitial Thermal Therapy for Glioblastoma of the Corpus Callosum. ( 29438526 )
2018
5
Overexpression of centrosomal protein 55 regulates the proliferation of glioma cell and mediates proliferation promoted by EGFRvIII in glioblastoma U251 cells. ( 29434995 )
2018
6
Hypofractionated Re-irradiation after Maximal Surgical Resection for Recurrent Glioblastoma: Therapeutic Adequacy and Its Prognosticators of Survival. ( 29436186 )
2018
7
microRNA-598 inhibits cell proliferation and invasion of glioblastoma by directly targeting metastasis associated in colon cancer-1. ( 29444745 )
2018
8
Cucurbitacin B induces inhibitory effects via CIP2A/PP2A/Akt pathway in glioblastoma multiforme. ( 29393542 )
2018
9
Glioblastoma as differential diagnosis of autoimmune encephalitis. ( 29383516 )
2018
10
Hyaluronic Acid-Modified Micelles Encapsulating Gem-C<sub>12</sub>and HNK for Glioblastoma Multiforme Chemotherapy. ( 29397747 )
2018
11
Identification of microRNAs differentially expressed in glioblastoma stem-like cells and their association with patient survival. ( 29434344 )
2018
12
Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes. ( 29444930 )
2018
13
ATM and p53 combined analysis predicts survival in glioblastoma multiforme patients: a clinicopathologic study. ( 29369420 )
2018
14
T Cell Exhaustion Signatures Vary with Tumor Type and are Severe in Glioblastoma. ( 29437767 )
2018
15
Intracellular cholesterol level regulates sensitivity of glioblastoma cells against temozolomide-induced cell death by modulation of caspase-8 activation via death receptor 5-accumulation and activation in the plasma membrane lipid raft. ( 29162448 )
2018
16
The Urokinase Receptor Induces a Mesenchymal Gene Expression Signature in Glioblastoma Cells and Promotes Tumor Cell Survival in Neurospheres. ( 29445239 )
2018
17
Glioblastoma multiforme: another potential application for<sup>68</sup>Ga-PSMA PET/CT as a guide for targeted therapy. ( 29387926 )
2018
18
Antagonistic effects of nitric oxide in a glioblastoma photodynamic therapy model:mitigation by BET bromodomain inhibitor JQ1. ( 29440272 )
2018
19
Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis. ( 29105080 )
2018
20
Stereotactic Radiosurgery in the Multimodality Management of Residual or Recurrent Glioblastoma Multiforme. ( 29393176 )
2018
21
Perphenazine and prochlorperazine induce concentration-dependent loss in human glioblastoma cells viability. ( 29441946 )
2018
22
Cell biology of glioblastoma multiforme: from basic science to diagnosis and treatment. ( 29387965 )
2018
23
Inhibition of GLO1 in Glioblastoma Multiforme Increases DNA-AGEs, Stimulates RAGE Expression, and Inhibits Brain Tumor Growth in Orthotopic Mouse Models. ( 29385725 )
2018
24
Development of an exercise intervention as part of rehabilitation in a glioblastoma multiforme survivor during irradiation treatment: a case report. ( 29382243 )
2018
25
Semantic imaging features predict disease progression and survival in glioblastoma multiforme patients. ( 29442128 )
2018
26
Dexamethasone-Mediated Upregulation of Calreticulin Inhibits Primary Human Glioblastoma Dispersal Ex Vivo. ( 29443896 )
2018
27
Management of Elderly patients with Glioblastoma - Multiforme. ( 29376741 )
2018
28
CircSMARCA5 Inhibits Migration of Glioblastoma Multiforme Cells by Regulating a Molecular Axis Involving Splicing Factors SRSF1/SRSF3/PTB. ( 29415469 )
2018
29
Presence of apoptosis distinguishes primary central nervous system lymphoma from glioblastoma during intraoperative consultation. ( 29336777 )
2018
30
Early candidate biomarkers found from urine of glioblastoma multiforme rat before changes in MRI. ( 29372508 )
2018
31
Autophagy activation promotes bevacizumab resistance in glioblastoma by suppressing Akt/mTOR signaling pathway. ( 29434840 )
2018
32
Reactive Astrocytes in Glioblastoma Multiforme. ( 29363044 )
2018
33
Does radiation therapy increase gadolinium accumulation in the brain?: Quantitative analysis of T1 shortening using R1 relaxometry in glioblastoma multiforme patients. ( 29444157 )
2018
34
MicroRNA-370 suppresses the progression and proliferation of human astrocytoma and glioblastoma by negatively regulating I^-catenin and causing activation of FOXO3a. ( 29399110 )
2018
35
Impact of PKCI/ downregulation on autophagy in glioblastoma cells. ( 29439667 )
2018
36
Significant effect of anti-tyrosine kinase inhibitor (Gefitinib) on overall survival of the Glioblastoma (GBM) patients in the backdrop of mutational status of EGFR and PTEN genes. ( 29444555 )
2018
37
Intraoperative Flow Cytometry Enables the Differentiation of Primary Central Nervous System Lymphoma from Glioblastoma. ( 29330078 )
2018
38
New aspects of glioblastoma multiforme revealed by similarities between neural and glioblastoma stem cells. ( 29383547 )
2018
39
The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials. ( 28266716 )
2018
40
Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy. ( 29378529 )
2018
41
Comparative proteomics as a tool for identifying specific alterations within interferon response pathways in human glioblastoma multiforme cells. ( 29416731 )
2018
42
Vitamin D receptor protects glioblastoma A172A cells against Coxsackievirus A16 infection induced cell death in the pathogenesis of hand, foot, and mouth disease. ( 28943436 )
2017
43
Biological basis and clinical study of glycogen synthase kinase- 3I^-targeted therapy by drug repositioning for glioblastoma. ( 28423558 )
2017
44
Interaction between transcription factors PAX6/PAX6-5a and specific members of miR-183-96-182 cluster, may contribute to glioma progression in glioblastoma cell lines. ( 28184912 )
2017
45
Tumor Location and Survival Outcomes in Adult Patients with Supratentorial Glioblastoma by Levels of Toll-Like Receptor 9 Expression. ( 27744078 )
2017
46
Secreted Glioblastoma Nanovesicles Contain Intracellular Signaling Proteins and Active Ras Incorporated in a Farnesylation-dependent Manner. ( 27909058 )
2017
47
Docetaxel-Loaded Nanoparticles Assembled from I^-Cyclodextrin/Calixarene Giant Surfactants: Physicochemical Properties and Cytotoxic Effect in Prostate Cancer and Glioblastoma Cells. ( 28533751 )
2017
48
DNM3, p65 and p53 from exosomes represent potential clinical diagnosis markers for glioblastoma multiforme. ( 29449895 )
2017
49
HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cells. ( 28342984 )
2017
50
A 4-miRNAs signature predicts survival in glioblastoma multiforme patients. ( 28869437 )
2017